HCPCS Code J9305: Injection, Pemetrexed, Not Otherwise Specified, 10 mg

HCPCS Code J9305: Injection, Pemetrexed, Not Otherwise Specified, 10 mg

HCPCS Code J9305 covers injection pemetrexed 10 mg for cancer treatment, including lung cancer and mesothelioma, billed per unit intravenously.

Use Code
## **What is HCPCS code J9305?** HCPCS code J9305 describes “Injection, pemetrexed, not otherwise specified, 10 mg.” Pemetrexed is a chemotherapy drug primarily used in the treatment of malignant pleural mesothelioma and advanced or metastatic non-small cell lung cancer. The medication is often part of combination cancer regimens and its effectiveness has been demonstrated in improving survival outcomes in eligible patients. Because pemetrexed is cleared by the kidneys, documentation and billing should reflect appropriate monitoring of kidney function and any adjustments to medications or supportive care given during the procedure. This J-code represents the drug itself, not the administration. Claims must report the number of units based on the dosage given, with each unit corresponding to 10 mg of pemetrexed. The actual administration—such as infusion or injection—is billed separately under the appropriate CPT chemotherapy administration codes. J9305 is a CMS Level II HCPCS code categorized under chemotherapy drugs. It ensures proper coding and reimbursement for pemetrexed when supplied in physician offices, hospital outpatient departments, and other Medicare Part B-covered settings. Accurate claims require linking J9305 with the correct diagnosis codes that support medical necessity, such as those for non-small cell lung cancer or mesothelioma, and following payer-specific rules for oncology drug coverage. Clear documentation of the patient’s health status, kidney function, concurrent medications, and the procedure performed helps ensure compliance, safety, and billing accuracy.
## **HCPCS Code J9305 documentation requirements** Accurate documentation is essential when billing. Medicare and other payers require complete, detailed records that demonstrate medical necessity and compliance with drug billing policies. ### **Physician’s order** The medical record must include a valid physician’s order specifying pemetrexed as the prescribed drug. The order should clearly specify the dosage, route of administration, frequency, and treatment plan, all of which are consistent with the patient’s diagnosis. ### **Drug details and dosage** Documentation must record the exact dose of pemetrexed given, reported in 10 mg increments, along with the route of administration (typically intravenous infusion). The total milligrams prepared, administered, and if applicable, discarded must all be documented. ### **Modifiers for wastage** Medicare requires the use of JW and JZ modifiers for single-use vials. JW must be appended to report the amount of drug discarded, while JZ is required when no amount was discarded. The medical record must support the billed units and wastage amounts. ### **Medical necessity** The patient’s diagnosis must be documented in the record to establish medical necessity. Pemetrexed is primarily used for non-small cell lung cancer and malignant pleural mesothelioma, so diagnosis codes must align with accepted indications and payer policy. ### **Proof of administration** The record must reflect that pemetrexed was prepared and administered to the patient, including details such as the date of service, the setting of care, and the provider who administered the drug. While infusion times are required for chemotherapy administration CPT codes, they are not required for the J9305 drug code itself. ### **Payer-specific requirements** Medicare Administrative Contractors (MACs) and commercial payers may impose additional documentation requirements, such as prior authorization or specific diagnosis code edits. Providers should always confirm local policy before billing.
## **HCPCS Code J9305 billing requirements** Billing for HCPCS Code J9305 must follow CMS and Medicare Part B drug billing rules to ensure proper reimbursement. The code represents “Injection, pemetrexed, not otherwise specified, 10 mg” and is billed based on the exact dosage administered. ### **Units of service** Providers must bill J9305 in 10 mg increments, reporting the total dosage given to the patient. The claim should reflect the number of 10 mg units administered, and Medicare allows a maximum of 999 units per claim line. ### **Modifiers** JW and JZ modifiers apply to single-dose vials. JW is used to report any discarded drug, while JZ is used when no drug was discarded. For route of administration, JA should be used with the J-code for intravenous delivery, while JB is used for subcutaneous delivery. ### **Administration reporting** The J9305 code covers only the drug itself. Administration services such as intravenous infusion must be reported separately using the appropriate CPT chemotherapy administration codes, such as 96413 for IV infusion. ### **Diagnosis linkage** Claims must include diagnosis codes that demonstrate medical necessity for pemetrexed. The drug is primarily covered for indications such as non-small cell lung cancer and malignant pleural mesothelioma. Payer-specific rules and Medicare Administrative Contractor policies must be reviewed to confirm coverage for each claim.
## **Other relevant codes** - **J9304**: Injection, pemetrexed (Pemfexy), 10 mg - **J9294**: Injection, pemetrexed (Hospira), 10 mg, not therapeutically equivalent to J9305 - **J9296**: Injection, pemetrexed (Accord), 10 mg, not therapeutically equivalent to J9305 - **J9297**: Injection, pemetrexed (Sandoz), 10 mg, not therapeutically equivalent to J9305 - **J9314**: Injection, pemetrexed (Teva), 10 mg, not therapeutically equivalent to J9305 - **J9322**: Injection, pemetrexed (BluePoint), 10 mg, not therapeutically equivalent to J9305 - **J9323**: Injection, pemetrexed ditromethamine, 10 mg - **J9324**: Injection, pemetrexed (Pemrydi RTU), 10 mg

Frequently asked questions

HCPCS code J9305 is for injection, pemetrexed, not otherwise specified, 10 mg, used in chemotherapy treatment for eligible patients with advanced cancers.

Pemetrexed is an antimetabolite chemotherapy drug that interferes with cell growth. It is administered intravenously, often in combination with other drugs like docetaxel, and is generally used for treating non-small cell lung cancer and mesothelioma.

Alimta (pemetrexed) is typically used for non-small cell lung cancer and mesothelioma, not commonly for ovarian cancer.

The J code for pemetrexed (Alimta) is J9305 for injection, 10 mg per unit.

EHR and practice management software

Get started for free

*No credit card required

Free

$0/usd

Unlimited clients

Telehealth

1GB of storage

Client portal text

Automated billing and online payments